Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA.
Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA.
Diabetes Care. 2022 Feb 1;45(2):416-424. doi: 10.2337/dc21-1535.
Preclinical research implicates hypothalamic glial cell responses in the pathogenesis of obesity and type 2 diabetes (T2D). In the current study we sought to translate such findings to humans by testing whether radiologic markers of gliosis in the mediobasal hypothalamus (MBH) were greater in individuals with obesity and impaired glucose homeostasis or T2D.
Using cross-sectional and prospective cohort study designs, we applied a validated quantitative MRI approach to assess gliosis in 67 adults with obesity and normal glucose tolerance, impaired glucose tolerance (IGT), or T2D. Assessments of glucose homeostasis were conducted via oral glucose tolerance tests (OGTT) and β-cell modeling.
We found significantly greater T2 relaxation times (a marker of gliosis by MRI), that were independent of adiposity, in the groups with IGT and T2D as compared with the group with normal glucose tolerance. Findings were present in the MBH, but not control regions. Moreover, positive linear associations were present in the MBH but not control regions between T2 relaxation time and glucose area under the curve during an OGTT, fasting glucose concentrations, hemoglobin A1c, and visceral adipose tissue mass, whereas negative linear relationships were present in the MBH for markers of insulin sensitivity and β-cell function. In a prospective cohort study, greater MBH T2 relaxation times predicted declining insulin sensitivity over 1 year.
Findings support a role for hypothalamic gliosis in the progression of insulin resistance in obesity and thus T2D pathogenesis in humans.
临床前研究表明,下丘脑胶质细胞反应与肥胖和 2 型糖尿病(T2D)的发病机制有关。在目前的研究中,我们试图通过测试肥胖和葡萄糖稳态受损或 T2D 个体的中脑基底部(MBH)胶质增生的放射学标志物是否更大,将这些发现转化为人类。
我们使用横断面和前瞻性队列研究设计,应用经过验证的定量 MRI 方法评估 67 名肥胖且葡萄糖耐量正常、葡萄糖耐量受损(IGT)或 T2D 成人的 MBH 胶质增生。通过口服葡萄糖耐量试验(OGTT)和β细胞建模评估葡萄糖稳态。
与葡萄糖耐量正常组相比,IGT 和 T2D 组的 T2 弛豫时间(MRI 胶质增生的标志物)显著增加,且与肥胖无关。这些发现存在于 MBH 中,但不存在于对照区域。此外,在 MBH 中存在正线性关联,但在对照区域不存在,MBH 中的 T2 弛豫时间与 OGTT 期间的血糖曲线下面积、空腹血糖浓度、糖化血红蛋白和内脏脂肪组织质量呈正相关,而在 MBH 中与胰岛素敏感性和β细胞功能的标志物呈负线性相关。在一项前瞻性队列研究中,MBH 的 T2 弛豫时间增加预示着胰岛素敏感性在 1 年内下降。
这些发现支持在肥胖和人类 T2D 发病机制中,下丘脑胶质增生在胰岛素抵抗进展中的作用。